The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Favorable toxicity of chemoradiation for muscle-invasive bladder cancer in elderly, frail patients.
 
Assaf Moore
Honoraria - Merck; Roche
 
Zhigang Zhang
No Relationships to Disclose
 
Bernard H. Bochner
Honoraria - Genentech/Roche
Consulting or Advisory Role - Genentech/Roche; Olympus
 
Timothy F. Donahue
No Relationships to Disclose
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina
Honoraria - Clinical Care Options; EMD Serono; Intellisphere; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource; Research To Practice; UpToDate
Consulting or Advisory Role - Adicet Bio; Astellas Pharma; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Immunomedics; Infinity Pharmaceuticals; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer/EMD Serono; Pharmacyclics; QED Therapeutics; Roche/Genentech; Seagen; Tyra Biosciences; western oncolytics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); QED Therapeutics (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
 
Gopa Iyer
Consulting or Advisory Role - Basilea; Bayer; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Speakers' Bureau - Gilead Sciences; Lynx Group
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Seagen (Inst)
 
Samuel Aaron Funt
Employment - ByHeart (I)
Stock and Other Ownership Interests - Allogene Therapeutics; IconOVir Bio; Kite, a Gilead company; Kronos Bio; Neogene Therapeutics; Urogen pharma; Vida Ventures
Consulting or Advisory Role - Immunai; Merck
Research Funding - AstraZeneca (Inst); Decibel Therapeutics (Inst); Genentech/Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb
 
Dean F. Bajorin
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Dragonfly Therapeutics; Fidia Farmaceutici S. p. A.; Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas (Inst)
Travel, Accommodations, Expenses - Merck
 
Min Yuen Teo
Consulting or Advisory Role - Janssen Oncology
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Pharmacyclics (Inst)
 
David Henry Aggen
Consulting or Advisory Role - Boehringer Ingelheim
Patents, Royalties, Other Intellectual Property - University of Illinois - Urbana Champaign
 
Daniel Gorovets
No Relationships to Disclose
 
David Guttmann
No Relationships to Disclose
 
Michael J. Zelefsky
Consulting or Advisory Role - Alpha Tau; Boston Scientific
Research Funding - Bayer; Novartis
 
Marisa Kollmeier
No Relationships to Disclose